Prostate cancer, tumorimmunity and a renewed sense of optimism in immunotherapy

Nicolò Rigamonti, Matteo Bellone

Research output: Contribution to journalArticlepeer-review


The recent FDA approval of the first therapeutic vaccine against prostate cancer has revitalized the public interest in the fields of cancer immunology and immunotherapy. Yet, clinical results are modest. A reason for this limited success may reside in the capacity of the tumor to convert inflammation in a tumor-promoting condition and eventually escape immune surveillance. Here we present the main known interactions between the prostate tumor and the immune system, showing how the malignancy can dodge the immune system by also exerting several immunosuppressive mechanisms. We also discuss experimental and clinical strategies proposed to counteract cancer immune evasion and emphasize the importance of implementing appropriate murine models like the transgenic adenocarcinoma of the mouse prostate model for investigating the biology of prostate cancer and novel immunotherapy approaches against it.

Original languageEnglish
Pages (from-to)453-468
Number of pages16
JournalCancer Immunology, Immunotherapy
Issue number4
Publication statusPublished - Apr 2012


  • Immunosuppression
  • Immunotherapy
  • Mouse model
  • Prostate cancer
  • Tumor immunity

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Immunology
  • Immunology and Allergy
  • Medicine(all)


Dive into the research topics of 'Prostate cancer, tumorimmunity and a renewed sense of optimism in immunotherapy'. Together they form a unique fingerprint.

Cite this